Clinical trials: Varicella Zoster
Herpes Zoster
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as…
- Trial name
- NCT03439657
- Testing
- HZ/su vaccine GSK1437173A, Prevenar13
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpse Zoster
A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine
Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.
- Trial name
- NCT07753265
- Testing
- live-attenuated zoster vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic…
- Trial name
- NCT01527383
- Testing
- V212
- Volunteers
- 354 people
- Sponsor
- Merck Sharp & Dohme LLC
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses…
- Trial name
- NCT05015686
- Testing
- Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd, Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- Where
- China
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella (Chickenpox)
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines.
- Trial name
- NCT07415252
- Testing
- NBP608 (Mid Potency), NBP608 (Low Potency), Varivax®
- Where
- 14 sites in Honduras, Philippines and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Varicella
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.
- Trial name
- NCT03843632
- Testing
- VARIVAX™
- Where
- 5 sites in Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Postherpetic Neuralgia
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
- Trial name
- NCT00652184
- Testing
- valaciclovir
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- aRigen Pharmaceuticals, Inc.
Herpes Zoster, Neuralgia
Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products.
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00082316
- Testing
- Capsaicin Dermal Patch
- Where
- 17 sites in United States
- Sponsor
- NeurogesX
Healthy
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.
- Trial name
- NCT00092417
- Testing
- Comparator: Varicella Zoster Virus Vaccine
- Volunteers
- 695 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rubella, Varicella
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated…
- Conditions
- Rubella, Varicella, Measles, Mumps
- Trial name
- NCT01506193
- Testing
- PriorixTetra™, Meningitec
- Where
- 13 sites in Italy
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peripheral Nervous System Diseases, Pain
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).
- Conditions
- Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster
- Trial name
- NCT00115310
- Testing
- NGX-4010
- Volunteers
- 400 people
- Sponsor
- NeurogesX
Postherpetic Neuralgia
Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia
This is a Phase 2 randomized, double-blind, placebo-controlled, multiple-dose, multicenter, parallel-group study to evaluate the analgesic activity of ATx08-001, a novel selective peroxisome proliferator-activated receptor…
- Trial name
- NCT01318226
- Testing
- ATx08-001
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Aestus Therapeutics
Shingles
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
- Trial name
- NCT00534248
- Testing
- Zoster Vaccine, Live (Zostavax™)
- Volunteers
- 22,439 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Treatment of PHN
3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)
Post-herpetic neuralgia (PHN) is pain following acute herpes zoster; defined as pain lasting longer than 3 months. Current first line management consists of tricyclic anti-depressants and anti-convulsants such as gabapentin and…
- Trial name
- PHN (NCT03421613)
- Testing
- 3VM1001
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- CDA Research Group, Inc.
Varicella
A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
This study is a randomized and controlled Phase IV clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of combined immunization with live attenuated varicella vaccine and inactivated hepatitis A…
- Trial name
- NCT05526820
- Testing
- The live attenuated varicella vaccine and the inactivated hepatitis A vaccine
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster, Varicella-zoster Vaccine
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose.
- Trial name
- NCT01245751
- Testing
- Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer
The goal of this clinical trail is to demonstrate the non-inferiority of recombinant human interferon α-2b gel (ZK-A03) after changing the manufacturer of the active ingredient in patients with herpes zoster.
- Trial name
- NCT05806918
- Testing
- Recombinant Human Interferon α-2b Gel (After the Alteration), Recombinant Human Interferon α-2b Gel (Before the Alteration)
- Volunteers
- 368 people
- Sponsor
- Lee's Pharmaceutical Limited
Cardiovascular Disease
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in…
- Trial name
- NCT07712380
- Testing
- Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline